Discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
This is an established company with proven profits.
Average growth of 26% a year over the last 4 years. Every year shown ended in profit.
If every debt were paid off today, $1.1B would still be left in the vault — a solid cushion for hard times.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
Debt is low and cash is strong; the finances stand solid.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Clearly above the class average — a step short of the very top.
Clearly above the class average — a step short of the very top.
No real weak spot in any of the five subjects — a balanced report card.
The stock trades 16% below its peak. The market has trimmed its expectations for the company.
The net profit margin is 17% — that slice of every sale is the company’s cushion in hard quarters.
Over the last 4 years, sales grew about 26% a year on average.
There is $1.5B in the vault; even if every debt were paid off, $1.1B would remain.
The company’s market value is 33 times its annual profit. Even a small disappointment could hit the price hard.
On our five-subject report card, NBIX sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: NBIX is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s what that quality should cost.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (59/100) says the stock isn’t cheap.